Table 1.
Participant demographics for the full sample and by secondary progressive and primary progressive multiple sclerosis subtypes.
| Full sample (n = 114) | SPMS (n = 80, 70%) | PPMS (n = 34, 30%) | p-value | |
|---|---|---|---|---|
| Age (years): mean (sd) | 59.2 (8.5) | 58.6 (8.2) | 60.4 (9.2) | 0.32 |
| Female: n (%) | 62 (54.4%) | 48 (60.0%) | 14 (41.2%) | 0.10 |
| White race: n (%)a | 104 (91.2%) | 72 (90.0%) | 32 (94.1%) | 0.72 |
| Ever smoked: n (%) | 53 (46.5%) | 37 (46.3%) | 16 (47.1%) | >0.99 |
| Bachelor's degree or higher: n (%) | 58 (50.9%) | 42 (52.5%) | 16 (47.1%) | 0.81 |
| Duration of disease since first symptom onset (years): mean (sd) | 22.4 (11.3) | 25.0 (11.0) | 16.2 (9.5) | < 0.01 |
| EDSS: median (IQR) | 6.0 (4.0–6.0) | 6.0 (4.0–6.5) | 5.5 (3.6–6.0) | 0.06 |
| Clinical and/or radiographic relapse in the 5 years prior to entry: n (%) | 27 (23.7%) | 18 (22.5%) | 9 (26.5%) | 0.63 |
| Taking DMT: n (%) | 63 (55.3%) | 45 (56.3%) | 18 (52.9%) | 0.84 |
| Interferons/glatiramer/teriflunomide: n (%)b | 12 (19.0%) | 11 (24.4%) | 1 (5.6%) | 0.15 |
| DMF/fingolimod: n (%)b | 14 (22.2%) | 11 (24.4%) | 3 (16.7%) | 0.74 |
| CD20 B cell therapy: n (%)b | 32 (50.8%) | 18 (40.0%) | 14 (77.8%) | 0.01 |
| Natalizumab: n (%)b | 5 (7.9%) | 5 (11.1%) | 0 (0.0%) | 0.31 |
a
Other races were Black (4.4%), more than one race (2.6%), Asian (0.9%), Unknown (0.9%).
b
Percentage of those taking DMT.
DMF, dimethyl fumarate; DMT, disease-modifying therapy; EDSS, Expanded Disability Status Scale; IQR, interquartile range; PPMS, primary progressive multiple sclerosis; SPMS, secondary progressive multiple sclerosis; sd, standard deviation.